New drug duo aims to keep relapsed germ cell cancer in check
NCT ID NCT06937866
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking two drugs (zanzalintinib and oral etoposide) after high-dose chemotherapy can help keep relapsed germ cell tumors from growing. About 38 adults whose cancer has not been cured by standard treatments will participate. The goal is to see if this combination is safe and can delay cancer progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Dose chemo with stem cell transplant tested against standard therapy for tough germ cell cancers
- Could a dementia drug shield kids' brains from radiation damage?
- Dietary change explored as cancer support strategy
- Hypnosis may ease chemo anxiety in teens and young adults
- New proton beam study aims to cut cancer treatment side effects
- Could a simple pill keep relapsed testicular cancer at bay?